Friday, 21 Sep 2018

You are here

Fish Oil Fails in Dry Eye Trial

Many topical and OTC products are recommended when treating chronic dry eyes, including omega-3 fatty acids (fish oil or n−3 fatty acids) to relieve symptoms; the NEJM reports that the DREAM trial shows no clinical benefit of n−3 fatty acids for 12 months when compared to placebo.

Patients (n=535) with moderate-to-severe dry eye disease were randomized (2:1) to receive daily oral dose of 3000 mg of fish-derived n−3 eicosapentaenoic and docosahexaenoic acids or an olive oil placebo (placebo group). The primary outcome was the mean change from baseline in the score on the Ocular Surface Disease Index (OSDI; scores on a 0 to 100 scale.

At 12 months, the mean change in the OSDI (dry eye) score was not significantly different between the active supplement group and the placebo group (−13.9 points and −12.5 points, respectively (P=0.21). Likewise there were no differences in secondary outcomes (conjunctival staining score, corneal staining score, tear break-up time or Schirmer’s test).

Rates of adverse events were similar in the two trial groups.

Patients with chronic dry eys treated with n-3 fatty acids failed to achieve significantly better outcomes than those on placebo. (DREAM ClinicalTrials.gov number, NCT02128763.)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.